Table 2.

Primary and secondary efficacy endpoints

End point	Category	Placebo (n = 19)	Dotinurad
			1 mg (n = 20)	2 mg (n = 19)	4 mg (n = 21)
Percent change in serum uric acid level from the baseline to the final visit	Mean ± SD	0.85 ± 14.53	37.03 ± 8.92	50.91 ± 10.61	64.37 ± 7.67
	95% Confidence Interval	− 6.15 to 7.86	32.85 to 41.21	45.80 to 56.03	60.88 to 67.86
	Jonckheere–Terpstra test	P < 0.001*
	Tukey–Kramer test	–	P < 0.001*	P < 0.001*	P < 0.001*
Percentage of patients with a serum uric acid level ≤ 6.0 mg/dL at the final visit	Number (%)	0 (0.0)	15 (75.0)	17 (89.5)	20 (95.2)
	95% Confidence Interval	0.0 to 17.6	50.9 to 91.3	66.9 to 98.7	76.2 to 99.9
	Cochran–Armitage test	P < 0.001*
	χ2 test	–	P < 0.001*	P < 0.001*	P < 0.001*

Jonckheere–Terpstra test and Cochran–Armitage test were used to evaluate dose dependency in the groups of 1 mg, 2 mg, and 4 mg, and placebo

Tukey–Kramer test and χ² test were adjusted about placebo vs. each dotinurad group

*P < 0.05